MARKET

BHC

BHC

Bausch Health Companies Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

19.17
-0.07
-0.36%
After Hours: 19.25 +0.08 +0.42% 17:48 11/25 EST
OPEN
19.08
PREV CLOSE
19.24
HIGH
19.32
LOW
18.84
VOLUME
3.68M
TURNOVER
--
52 WEEK HIGH
31.97
52 WEEK LOW
11.15
MARKET CAP
6.81B
P/E (TTM)
-3.5190
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Saudi, Abu Dhabi Wealth Funds Team Up on Egyptian Drugmaker Deal
(Bloomberg) -- Two of the biggest sovereign wealth funds in the Middle East are exploring a joint bid for an Egyptian pharmaceutical company, a deal that could mark the beginning of wider co-investment plans between the two state-controlled firms, people familiar with the matter said.Saudi Arabia’s Public Investment Fund and ADQ, formerly known as Abu Dhabi Development Holding Co., are weighing the purchase of Bausch Health Cos.’s Cairo-based drug unit, the people said, asking not to be identified because negotiations are private. In addition, the two funds have held talks to work closely on other transactions in areas such as food security, health care and industrials, the people said.A representative for ADQ wasn’t available to comment. The PIF and Bausch declined to comment. A spokesperson for Amoun didn’t answer two calls, or respond to a text message seeking comment.Fearing global supply disruptions, Gulf states have been buying overseas farmlands and investing in agricultural technology. Abu Dhabi, mostly through ADQ, intensified efforts during the coronavirus pandemic by acquiring a stake in agricultural trader Louis Dreyfus Co. and investing in Lulu Hypermarket Group’s expansion into Egypt. The PIF is said to be weighing an investment into the same supermarket chain operator.ADQ has been holding talks to acquire Bausch’s Egyptian business, known as Amoun Pharmaceutical Co., which could be valued at around $700 million, Bloomberg reported last month. Talks are ongoing and there’s no certainty the deliberations will lead to a transaction involving one or both of the funds, the people said.Bausch, formerly known as Valeant Pharmaceuticals International Inc., has been reshaping its operations since gaining infamy on Wall Street for raising drug prices. One activist investor, Glenview Capital, has been pushing Bausch to sell or spin off more businesses.On the BlockValeant sought a buyer for Amoun in 2016, a year after buying it for about $800 million to expand in the Middle East and Africa, according to people with knowledge of the matter at the time. Those discussions ended without a deal.ADQ owns major enterprises spanning key sectors of the Gulf emirate’s economy, including Abu Dhabi Securities Exchange and Abu Dhabi Airports. The fund, chaired by Sheikh Tahnoon Bin Zayed Al Nahyan, and another investor agreed last month to buy a $2.1 billion indirect stake in Abu Dhabi National Oil Co.’s natural gas pipelines.The PIF, which holds about $347 billion in assets, is a key lever for Crown Prince Mohammed bin Salman’s efforts to revive growth and get his economic master plan, known as Vision 2030, back on track following the fallout from the Covid-19 outbreak and lower oil prices.Saudi Wealth Fund Making Another Splash, This Time at HomeHanded $40 billion earlier this year to buy global stocks, the PIF will plow the same amount into the domestic economy next year and again in 2022. The fund intends to play a leading role in refocusing the economy toward underdeveloped industries like tourism and diversifying away from crude.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 10h ago
Bausch (BHC) Begins Second Phase III Study on NOV03 for DED
Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.
Zacks · 1d ago
Bausch Health launches second late-stage study for NOV03 for dry eye disease
Bausch Health Companies (BHC) and its global eye health business, Bausch + Lomb has initiated the second of two Phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) to treat
Seekingalpha · 2d ago
Bausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") and Bausch + Lomb, its leading global eye health business, announced today that the Company has initiated the second of
Benzinga · 2d ago
Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Conditional Redemption Of Additional Series Of Existing Senior Notes
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced and upsized its previously announced offering of $1.0 billion aggregate principal amount of 5.000% senior notes due 2029 (the "2029 Notes") and $1.0 billion aggregate principal amount of 5.250% senior notes due 2031 (the "2031 Notes" and, together with the 2029 Notes, the "Notes"). The size of the offering reflects an increase of $250 million from the previously announced offering size of $1.75 billion. The 2029 Notes will be sold to investors at a price of 100% of the principal amount thereof, and the 2031 Notes will be sold to investors at a price of 100% of the principal amount thereof.
PR Newswire · 11/18 21:51
Bausch Health launches private offering of senior notes
Bausch Health Companies (BHC) has launched an offering of a combined $1.75B of new senior notes due 2029 and new senior notes due 2031.The proceeds will be used to fund
Seekingalpha · 11/18 12:56
Certn named one of Canada's Companies-to-Watch in Deloitte's Technology Fast 50 Awards
VICTORIA, BC, Nov. 18, 2020 /CNW/ - Certn, a leading people data platform that helps businesses perform fast, comprehensive background checks and ongoing risk monitoring, is named one of Canada's Companies-to-Watch in the 2020 Deloitte Technology Fast 50™ Awards.
CNW Group · 11/18 11:00
Should Value Investors Consider Bausch Health (BHC) Now?
Let's see if Bausch Health (BHC) stock is a good choice for value-oriented investors right now from multiple angles.
Zacks · 11/17 15:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BHC. Analyze the recent business situations of Bausch Health Companies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BHC stock price target is 26.78 with a high estimate of 50.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 509
Institutional Holdings: 236.89M
% Owned: 66.70%
Shares Outstanding: 355.15M
TypeInstitutionsShares
Increased
98
19.21M
New
90
9.43M
Decreased
99
34.37M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Chief Executive Officer/Director
Joseph Papa
Chief Financial Officer/Executive Vice President
Paul Herendeen
Corporate Executive
Thomas Appio
Corporate Executive
Joseph Gordon
Corporate Executive
William Humphries
Executive Vice President/General Counsel
Christina Ackermann
Independent Director
Richard DeSchutter
Lead Director
Thomas Ross
Independent Director
Richard De Schutter
Independent Director
D. Robert Hale
Independent Director
Argeris Karabelas
Independent Director
Sarah Kavanagh
Independent Director
John Paulson
Independent Director
Robert Power
Independent Director
Russel Robertson
Independent Director
Andrew Charles von Eschenbach
Independent Director
Andrew von Eschenbach
Independent Director
Amy Wechsler
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/22/2010
Dividend USD 16.77
09/23/2010
05/05/2010
Dividend USD 0.095
05/31/2010
02/24/2010
Dividend USD 0.09
03/04/2010
11/04/2009
Dividend USD 0.09
11/30/2009
08/06/2009
Dividend USD 0.09
08/28/2009
05/06/2009
Dividend USD 0.09
05/13/2009
02/26/2009
Dividend USD 0.375
03/06/2009
11/06/2008
Dividend USD 0.375
12/19/2008
08/13/2008
Dividend USD 0.375
08/21/2008
05/08/2008
Dividend USD 0.375
05/20/2008
03/13/2008
Dividend USD 0.375
03/25/2008
11/08/2007
Dividend USD 0.375
11/16/2007
08/08/2007
Dividend USD 0.375
08/16/2007
05/10/2007
Dividend USD 0.375
05/17/2007
03/15/2007
Dividend USD 0.375
03/22/2007
12/06/2006
Dividend USD 0.5
01/08/2007
11/09/2006
Dividend USD 0.125
11/20/2006
08/03/2006
Dividend USD 0.0775
08/15/2006
05/11/2006
Dividend USD 0.125
05/18/2006
03/23/2006
Dividend USD 0.125
04/05/2006
02/28/2006
Dividend USD 0.0775
03/14/2006
11/15/2005
Dividend USD 0.5
11/28/2005
11/04/2005
Dividend USD 0.0775
11/15/2005
08/04/2005
Dividend USD 0.0775
08/17/2005
03/10/2005
Dividend USD 0.0775
04/11/2005
12/29/2004
Dividend USD 0.0775
01/10/2005
06/30/2004
Dividend USD 0.0775
07/12/2004
03/03/2004
Dividend USD 0.0775
04/12/2004
12/19/2003
Dividend USD 0.0775
01/12/2004
01/04/2001
Dividend USD 0.0725
01/10/2001
10/04/1999
Dividend USD 0.07
10/08/1999
06/22/1999
Dividend USD 0.07
07/12/1999
03/22/1999
Dividend USD 0.07
04/12/1999
01/12/1999
Dividend USD 0.06
01/20/1999
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BHC
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Bausch Health Companies Inc stock information, including NYSE:BHC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BHC stock methods without spending real money on the virtual paper trading platform.